GeoVax Market Capitalization from 2010 to 2024
| GOVX Stock | USD 2.70 0.31 10.30% |
Check GeoVax Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among GeoVax Labs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 70.5 K, Interest Expense of 48.6 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 324, Dividend Yield of 0.0 or PTB Ratio of 2.27. GeoVax financial statements analysis is a perfect complement when working with GeoVax Labs Valuation or Volatility modules.
GeoVax | Market Capitalization |
Latest GeoVax Labs' Market Capitalization Growth Pattern
Below is the plot of the Market Cap of GeoVax Labs over the last few years. It is GeoVax Labs' Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in GeoVax Labs' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 28.4 M | 10 Years Trend |
|
Market Cap |
| Timeline |
GeoVax Market Capitalization Regression Statistics
| Arithmetic Mean | 107,016,744 | |
| Geometric Mean | 85,549,133 | |
| Coefficient Of Variation | 43.67 | |
| Mean Deviation | 36,027,255 | |
| Median | 128,771,815 | |
| Standard Deviation | 46,730,616 | |
| Sample Variance | 2183.8T | |
| Range | 124.8M | |
| R-Value | (0.68) | |
| Mean Square Error | 1266.9T | |
| R-Squared | 0.46 | |
| Significance | 0.01 | |
| Slope | (7,097,027) | |
| Total Sum of Squares | 30572.5T |
GeoVax Market Capitalization History
About GeoVax Labs Financial Statements
GeoVax Labs investors use historical fundamental indicators, such as GeoVax Labs' Market Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in GeoVax Labs. Please read more on our technical analysis and fundamental analysis pages.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia. Geovax Labs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for GeoVax Stock Analysis
When running GeoVax Labs' price analysis, check to measure GeoVax Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeoVax Labs is operating at the current time. Most of GeoVax Labs' value examination focuses on studying past and present price action to predict the probability of GeoVax Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeoVax Labs' price. Additionally, you may evaluate how the addition of GeoVax Labs to your portfolios can decrease your overall portfolio volatility.